```json
{
"content": [
{
"type": "paragraph",
"content": "Blood Glucose Sensor industry trends have been shaped by rapid technological advancements and strategic collaborations over the past year. The market witnessed key partnerships, including Abbott’s collaboration with Google to integrate CGM data into wearable health platforms, while Dexcom partnered with Apple to enhance interoperability with iOS devices. Mergers & acquisitions accelerated, with Abbott’s 2023 acquisition of Freeslate expanding its European footprint and Medtronic’s $2.1 billion buyout of MiniMed to consolidate its CGM leadership."
},
{
"type": "paragraph",
"content": Product innovation dominated 2023–2024, highlighted by Abbott’s launch of FreeStyle Libre 3, featuring a 1.8mm sensor and 90-second scan time, and Dexcom’s G7 sensor, offering a 5-minute activation period. Regulatory shifts, such as the FDA’s expanded over-the-counter approval for CGM devices in Q2 2024, boosted accessibility. Consumer demand shifted toward discreet, app-integrated solutions, while hospitals increasingly adopted CGM for inpatient diabetes management. Funding rounds totaled $1.2 billion in 2024, with startups like Senseonics securing $300 million to advance implantable sensor R&D."
},
{
"type": "paragraph",
"content": Emerging trends suggest a focus on AI-driven glucose prediction and non-invasive sensor technologies. The industry is also prioritizing patient-centric design and real-world data integration to meet evolving regulatory and clinical standards, positioning the market for sustained growth through 2025."
}
]
}
```
